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Abstract  
A selection of 76 nitroheterocycles and related compounds from our in–house 
compound library was screened in vitro against the parasite Trypanosoma brucei 
rhodesiense, causative agent of human African trypanosomiasis (HAT). The unspecific 
cytotoxicity of the compounds was also evaluated against rat myoblast L6-cells to 
measure the selectivity of the compounds towards the parasite. This screening revealed 
some preliminary structure-activity relationships (SAR) among the series, and six hit 
compounds showing interesting activity (IC50 ≤ 10 µM) and fair selectivity (SI > 17). 
The 7-nitroquinoxalin-2-one and 5-nitroindazole scaffold derivatives 58 and 35, 
respectively, are particularly interesting because of their established oral bioavailability 
in mice. These hits represent interesting starting points for a medicinal project aimed at 
identifying the SAR behind this class of compounds. 
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 CNS, central nervous system; DNDi, Drugs for Neglected Diseases initiative; HAT, 
human African trypanosomiasis; IC50, 50% inhibitory concentration; MEM, minimum 
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Human African trypanosomiasis (HAT), also known as sleeping sickness, is a neglected 
tropical disease (NTD) endemic in sub-Saharan Africa. The causative agents are the 
protozoan parasites Trypanosoma brucei rhodesiense and T. b. gambiense which 
provoke acute and chronic forms of the disease, respectively. The parasites are 
transmitted by the bite of infected tsetse flies. In absence of treatment, the parasites 
present in the blood and lymph during early stage HAT invade the central nervous 
system (CNS) provoking the fatal meningoencephalitic (late) stage of the disease.
1, 2
 
The NTD status of sleeping sickness is highlighted by the fact that 3 out of the 4 drugs 
approved for its treatment (i.e., pentamidine, melarsoprol, suramin) were discovered 
more that 60 years ago. The other drug, eflornithine, was approved in 1990 for the 
treatment of late-stage T. b. gambiense infection. Other authors have reviewed the 
shortcomings of those drugs especially regarding toxicity, lack of oral bioavailability or 
lack of efficiency.
3
 Apart from the recent inclusion of the nifurtimox-eflornithine 
combination therapy (NECT) in the WHO list of essential medicines, no new drugs 
have been registered for HAT in the last 20 years 
(http://www.who.int/selection_medicines/committees/expert/17/application/nifurtimox/
en/index.html).  
In the last years, the public-private partnership research efforts of the Drugs for 
Neglected Diseases initiative (DNDi) have been rewarded by the discovery of two 
potential drug candidates (the nitroimidazole fexinidazole and the oxaborole SCYX-
7158, Fig. 1) which have entered phase I clinical development for both acute and 
chronic sleeping sickness.
4, 5
 These were discovered by screening chemical libraries of 
compounds against African trypanosomes. The fact that a nitroimidazole derivative, 
fexinidazole, is one the most promising new drug candidate for the oral treatment of 
4 
both stages of HAT, despite the inherent caution usually associated with 
nitroheterocycles as drug candidates, led us to consider our library of nitroheterocycles 
as a possible source of new hits against African trypanosomes. In fact, some of our 
nitroheterocyclic compounds and related compounds have already shown interesting in 
vivo and/or in vitro activity against the protozoa T. cruzi, etiological agent of American 
trypanosomiasis (Chagas’ disease),
6-13
 Trichomonas vaginalis
13-18
 and Leishmania 
spp.;
10
 other compounds were effective inhibitors of biocrystallization of 
ferriprotoporphyrin IX (heme) to hemozoin and thus, potential antimalarial agents.
19, 20
 
Besides, it should be kept in mind that the nitroheterocycles benznidazole and 
nifurtimox (Fig. 1) are currently the only drugs available for the treatment of American 
trypanosomiasis which emphasizes the importance of this class of chemical structures as 
antiprotozoal agents.  
We report here the in vitro screening against T. b. rhodesiense (strain STIB900) 
of a selection of 76 nitro–derivatives of nitrogenated heterocycles (e.g., nitrocinnolines, 
nitroindoles, nitroindazoles and nitroquinoxalinones) and related compounds
13, 19, 21-30,
 
31
  
using the Alamar blue growth inhibition assay.
32
 Their cytotoxicity against mammalian 
L6-cells was also determined in vitro. This allowed the calculation of a selectivity index 
defined as: SI = IC50 (L6-cells) / IC50 (T. b. r.). This screening revealed some SAR 
among the series and a few hit compounds showing interesting activity and fair 
selectivity. These hits could be used as starting points for a medicinal chemistry 
optimization program.  
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Figure 1. Drugs currently in clinical development for the oral treatment of both stages 
of sleeping sickness (top) and drug used clinically against T. cruzi infections (bottom)  
 
Compounds from the hydrazide series (Table 1) had IC50 values against T. brucei in the 
range 5.5 to > 400 µM. Seven compounds showed IC50 < 50 µM (3, 11, 16, 17–20) but 
only three of those (3, 11, and 20) were selective for the parasite with SI of 8.3, 13.7, 
and 13, respectively. Of note is the effect of replacing the 6-halogen atom (Cl, F) by an 
ethoxy group in 20; this reduced significantly the cytotoxicity (13- to 57-fold) with only 
a two-fold decrease in antitrypanosomal activity with respect to 18 and 19.  
 
[insert Table 1 here] 
 
5-Nitroindazolols derivatives with free OH group (Table 2) were only weakly active 
against T. b. rhodesiense (IC50 > 63 µM). The best results, with IC50 values in the range 
5–12 µM and  SI = 5.3–11.6, were obtained with compounds bearing a basic amino side 
6 
chain such as 5-piperidinopentyl (34), 2-(2-piperidinoethoxy)ethyl (35), 2-
(dimethylamino)ethyl (38), and 3-(dimethylamino)propyl.  
 
[insert Table 2 here] 
 
Among indazolinone derivatives (Table 3), only 4 compounds (i.e., those holding a 
benzyl group on the N2 nitrogen) had IC50 < 50 µM (52–55) although with low 
selectivity (SI = 0.8–5.3). Compound 52 with N1-methyl-N2-benzyl substituents was 
the most active and selective of this series with IC50 = 8.2 µM and SI = 5.3. It is worth 
noting that increasing the size of the N1-substituent decreased significantly the activity 
of the compound in the order: methyl > propyl > butyl ≈ benzyl (i.e., 52–55). The 
regioisomer with N2-methyl-N1-benzyl substituents (51) was 20-times less active than 
52. 
[insert Table 3 here] 
 
The quinoxalin-2-one scaffold gave the best antitrypanosomal compounds with 6 
molecules (57, 58, 59, 60, 62, 65) having IC50 values < 15 µM and SI values in the 
range 3.6–39.7 (Table 4). The N1,N4-dimethyl compound 58 and the fused pyrrolidine 
derivative 65 were the most active compounds of this screening (IC50 = 3.6 and 2.7 µM, 
respectively). Methylation of the N1-nitrogen generally increased the activity by 
approximately 2-fold (compare 57 vs 58, 61 vs 62, and 69 vs 70) except for compounds 
66 and 67 where the opposite effect was observed. This substitution was generally 
accompagnied by an increase in cytotoxicity. Five and six methylene chloroalkyl chains 
7 
at N1 also gave low IC50 values (7.5 and 6.9 µM for 59 and 60, respectively) and fair 
selectivities (13.1 and 6.4, respectively). On the contrary, fused bulky rings such as 
piperidine (66–68), isoquinoline (69, 70), or benzo[d]azepine (63, 64) gave mostly 
cytotoxic compounds (i.e., SI < 1).  
The bisnitroindazole derivatives were poorly active against T. brucei (Table 5). The sole 
compound with interesting activity was the urea 76 which was one of the best hits of 
this study with IC50 = 7.1 µM and SI > 23.6. 
 
[insert Tables 4 and 5 here] 
 
The discovery of fexinidazole as a potential clinical candidate for the oral treatment of 
both stages of sleeping sickness has led, in the last years, to a renewed interest in 
nitroheterocyclic compounds as possible antitrypanosomal agents. In this study, we 
have taken advantage of our compound library, historically rich in nitroheterocyclic 
compounds, and selected 76 molecules from different groups to be tested against T. 
brucei (i.e., nitrobenzohydrazide, indazolol, indazolinone, quinoxalin-2-one, 
bisindazolols, etc.). From the data collected in this study, the SAR for anti-T. brucei 
activity is limited even though a few significant trends could be found for the 
quinoxalin-2-one and indazole series. In particular, the bulk around the N1-position of 
the molecule seems to be rather restricted. Thus, a small methyl substituent is allowed 
(57, 58) as well as fused pyrrolidine ring (65). Long alkylic chains are also favored (59, 
60) probably because they are quite flexible and can stay away from the steric restricted 
area around N1. On the contrary, bulkier fused substituents at N1 are detrimental to the 
activity. Important SAR results are depicted in Figure 2. 
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Figure 2. Summary of the hit compounds active against T. b. rhodesiense and selective 
over L6-cells. Important SAR features for anti-T. brucei activity are highlighted. 
 
Interestingly, several of the hits identified in this screening are also lead compounds 
against T. cruzi or T. vaginalis. On the one hand, 58 showed in vitro activity against 
epimastigotes and intracellular amastigotes of T. cruzi, as well as in vivo suppressive 
activity by oral route in a murine model of  acute T. cruzi infection.11 In the same study, 
Vega et al. showed that 65 was active but more cytotoxic that 58. Hence, despite the 
moderate selectivity for T. brucei over rat L6-cells (21.6-fold) found in our screening, 
58 seems to have adequate physicochemical properties for oral bioavailability and may 
well be an interesting lead compound worth investigating as anti-T. brucei agent. On the 
other hand, 34 was reported to be very active against T. vaginalis whilst its activity 
against T. cruzi was moderate.
13
 However, the 2-(2-piperidinoethoxy)ethyl analogue 35 
showed similar in vitro anti-T. cruzi efficacy with reduced cytotoxicity compared to 
9 
34;
10
 this finding is confirmed here as 34 has 2-fold higher cytotoxicity against L6-cells 
than 35. Besides, Boiani et al. have shown that 35 was active in vivo by oral 
administration in a murine model of acute Chagas’ infection indicating adequate 
bioavailability for this compound.
10
 These data indicate that 35 may also be a good 
trypanocidal lead for HAT.  
At this stage, the target and mode of action of these compounds against African 
trypanosomes remain unknown. In T. cruzi, the action of this kind of molecules seems 
to be associated with the production of reduced species of the 5-NO2 moiety similarly to 
what happens with benznidazole
8, 9
 or nifurtimox.
33
 Thus, the antitrypanosomal action 
of these compounds, like fexinidazole, could possibly involve bioreductive activation 
by parasite type I nitroreductase leading to reactive intermediates that would provoke 
cellular damage.
5, 34, 35
 Hall & Wilkinson have shown recently that the bioactivation of 
benznidazole by T. brucei type I nitroreductase generates the reactive dialdehyde 
glioxal which in turn leads to glyoxal-guanosine adducts. The authors suggest that the 
trypanocidal activity of benznidazole is the result of DNA damage by these 
metabolites.
36
 However, the nitroheterocycles reported here cannot be metabolized to 
glioxal by reductive activation. This means that other mechanism of action (or 
metabolites) may be involved. This hypothesis will need experimental confirmation. 
Altogether, the results of our in vitro screening against T. brucei take their importance 
in the light of the previous data of antiprotozoal activity reported for those compounds 
and related nitroimidazoles. For instance, the lead compound fexinidazole, which is 
currently in clinical trials for HAT, has IC50 values in the range 1.71–2.93 µM against T. 
b. rhodesiense STIB900 in the same assay.
5
 Even though fexinidazole selectivity (SI > 
322) is higher than that of our compounds, some of the hits presented here could be 
good starting points for an optimization program directed towards the discovery of new 
10 
antitrypanosomal agents for the treatment of sleeping sickness. This is the case, in 
particular, of the 7-nitroquinoxalin-2-one 58 and the 5-nitroindazole 35 that have 
demonstrated low micromolar activity and in vivo bioavailability in mice .  
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Table 1. In Vitro Activity of Hydrazides (1–20) and Related Compounds (21–22) 
against T. brucei rhodesiense. 
Cmpd Structure T. b. r.
a 
Cytotoxicity 
b
 SI ref.
c 
  IC50 (µM)   
1 
 
>419 68.4 0.2  
2 
 
166.2 241.1 1.5  
3 
 
40.2 >331 >8.3  
4 
 
97.3 19.8 0.2  
5 
 
>365 >365 1.0  
6 
 
179.8 168.1 0.9  
7 
 
320.3 >355 1.1 12 
8 
 
154.9 >359 2.3 12, 17, 20  
9 
 
>410 >410 1.0  
10 
 
211.8 >352 >1.7  
11 
O2N
F
N
H
N
O
 
23.1 >317 >13.7  
12 
 
55.5 22.0 0.4  
13 
 
82.2 179.7 2.2  
14 
 
>316 >316 1.0  
a 
 Trypanosoma brucei rhodesiense STIB900. Reference drug: melarsoprol, IC50 = 0.005 
16 
µM; 
b
 Rat skeletal myoblast L6-cells. Reference drug: podophyllotoxin, IC50 = 0.019 
µM; 
c 
Bibliographic reference related to other antiparasitic activities of the compound.
17 
Table 2. In Vitro Activity of Indazol-3-ol (23–39) and Cinnolin-3-ol (40) Derivatives 
against T. brucei rhodesiense. 
Cmpd Structure T. b. r.
a 
Cytotoxicity
b 
SI ref.
c 
  IC50 (µM)   
23 
 
>494 >494 1.0  
24 
 
192.1 >382 2.0 17 
25 
 
312.6 >517 1.7  
26 
 
194.3 >370 1.9 17, 20  
27 
 
191.0 222.3 1.2 17, 20 
28 
 
63.9 55.4 0.9 17, 20 
29 
 
146.2 216.7 1.5 15 
30 N
N
O2N
OH
F
 
168.1 210.3 1.3 17 
31 
 
109.3 157.5 1.4  
32 
 
63.3 >370 >5.8 17, 20 
a 
 Trypanosoma brucei rhodesiense STIB900. Reference drug: melarsoprol, IC50 = 0.005 
µM; 
b
 Rat skeletal myoblast L6-cells. Reference drug: podophyllotoxin, IC50 = 0.019 
µM.
 c 
Bibliographic reference related to other antiparasitic activities of the compound. 
18 
Table 3. In Vitro Activity of Indazolin-3-one (41–43, 45, 49-56) and Indolin-3-one (44, 
47, 48) Derivatives and Related Compounds (46) against T. brucei rhodesiense. 
19 
Cmpd Structure T. b. r.
a 
Cytotoxicity
b 
SI ref.
c 
  IC50 (µM)   
41 
 
427.2 >494 1.2 12, 17, 20 
42 
 
208.7 >404 1.9 17, 20 
43 
 
86.4 >338 >4  
44 
 
74.4 86.5 1.2 12, 17, 20 
45 
N
N
O
O2N
 
66.8 222.2 3.3  
46 
 
241.0 >263 1.1  
47 
 
197.7 268.6 1.4 12, 17, 20 
48 
 
212.9 84.9 0.4 17 
49 
 
162.6 233.6 1.4 17 
50 
N
H
N
O2N
O
N
 
252.0 286.5 1.1 17 
51 
 
162.7 165.5 1.0 12 
52 
 
8.2 43.4 5.3 12 
a 
 Trypanosoma brucei rhodesiense STIB900. Reference drug: melarsoprol, IC50 = 0.005 
20 
µM; 
b
 Rat skeletal myoblast L6-cells. Reference drug: podophyllotoxin, IC50 = 0.019 
µM. 
c 
Bibliographic reference related to other antiparasitic activities of the compound. 
21 
Table 4. In Vitro Activity of Quinoxalin-2-one (57–70) and Cinnolin-4-one (71) 
Derivatives against T. brucei rhodesiense. 
22 
Cmpd Structure T. b. r.
a 
Cytotoxicity
b 
SI ref.
c 
  IC50 (µM)   
57 
 
10.6 419.4 39.7 6, 16 
58 
 
3.6 78.2 21.6 11, 16 
59 
 
7.5 97.8 13.1 11, 16, 20 
60 
 
6.9 44.3 6.4 11, 16, 20 
61 
 
21.2 97.1 4.6 7, 18 
62 
 
14.6 52.3 3.6 7, 18 
63 
 
63.4 15.1 0.2  
64 
 
191.1 >311 1.6  
65 
 
2.7 46.7 17.4 11, 16 
66 
 
38.0 113.7 3.0 11, 16 
67 
 
153.5 101.8 0.7  
a 
 Trypanosoma brucei rhodesiense STIB900. Reference drug: melarsoprol, IC50 = 0.005 
23 
µM; 
b
 Rat skeletal myoblast L6-cells. Reference drug: podophyllotoxin, IC50 = 0.019 
µM. 
c 
Bibliographic reference related to other antiparasitic activities of the compound. 
24 
Table 5. In Vitro Activity of Bisindazole Derivatives (72–75) and 1,3-Disubstituted 
Urea 76 against T. brucei rhodesiense. 
Cmpd Structure T. b. r.
a 
Cytotoxicity
b 
SI ref.
c 
  IC50 (µM)   
72 
 
119.2 >204 1.7 19 
73 
 
80.5 >139 1.7 19 
74 
 
57.6 151.0 2.6 19 
75 
N
N
N
N
OMeOMe
 
100.6 44.7 0.4 19 
76 
 
7.1 >168 >23.6 17 
 
a 
 Trypanosoma brucei rhodesiense STIB900. Reference drug: melarsoprol, IC50 = 0.005 
µM; 
b
 Rat skeletal myoblast L6-cells. Reference drug: podophyllotoxin, IC50 = 0.019 
µM. 
c 
Bibliographic reference related to other antiparasitic activities of the compound. 
 
